A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ActivePure Medical Awarded Technology Breakthroughs Purchasing Agreement with Premier, Inc.

National Contracts Provide Access to Innovative, Continuous, and Whole-Facility Surface and Air Disinfection Technology

ActivePure Medical, LLC has been awarded a national group purchasing agreement for Facility Surface and Air Disinfection Technology with Premier, Inc. through its Technology Breakthroughs Program.

ActivePure Medical notes effective Feb. 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ActivePure Medical’s continuous, whole-room automated air and surface disinfection technology.

ActivePure Medical, the exclusive healthcare provider of ActivePure Technology, was created in 2020 after receiving clearance from the U.S. Food and Drug Administration (FDA) on their Class II Medical Device, the ActivePure Medical Guardian. The medical-grade device uses ActivePure’s patented and proprietary technology to create effective molecules that continuously fill the environment of care where they reduce airborne and surface pathogens.

“We are very excited to announce our Breakthrough status with Premier and to be awarded a GPO agreement. This national agreement allows ActivePure Medical to supply members with the best whole-room, automated surface and air disinfection technology developed for facility-wide coverage,” said ActivePure Medical President Dan Marsh. “Premier is a leader in the healthcare industry with a large network of health systems and members throughout the continuum of care, and we appreciate the company evaluating and awarding innovative technologies, like ActivePure, to ensure their members have access to the newest technologies available.”

All ActivePure Medical products were specifically designed for healthcare settings and have received California Air and Resource Board (CARB) Certification for no ozone production. ActivePure Medical will offer products to Premier customers that can be utilized in their current HVAC systems or portable units that are plug and play with no installation required. ActivePure Medical understands the staffing concerns of all healthcare facilities and developed its units to run automatically without an operator for 6-months or more.

The surge in COVID-19 cases has continued to result in not only significant shortages in healthcare staffing, but recent Centers for Disease Control and Prevention (CDC) data has shown that healthcare-associated infections (HAIs) have increased for the first time since 2015. Besides reducing Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Erwinia herbicola, Aspergillus niger, Bacillus globigii and Fungi, and other clinically relevant pathogens, ActivePure is extremely effective against SARS-CoV-2 responsible for COVID-19. The latest independent testing found ActivePure inactivated more than 99.98% of high concentration levels of the enveloped virus in one minute. All data can be found on the ActivePure Medical website, www.ActivePureMedical.com

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy